MENU
+Compare
BCAB
Stock ticker: NASDAQ
AS OF
Oct 14 closing price
Price
$0.80
Change
-$0.11 (-12.09%)
Capitalization
47.24M

BCAB BioAtla Forecast, Technical & Fundamental Analysis

BioAtla Inc is a clinical-stage biopharmaceutical company... Show more

BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for BCAB with price predictions
Oct 08, 2025

BCAB's RSI Indicator ascends into overbought territory

The RSI Indicator for BCAB moved into overbought territory on October 08, 2025. Be on the watch for a price drop or consolidation in the future -- when this happens, think about selling the stock or exploring put options.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCAB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BCAB broke above its upper Bollinger Band on October 08, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 03, 2025. You may want to consider a long position or call options on BCAB as a result. In of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BCAB just turned positive on October 06, 2025. Looking at past instances where BCAB's MACD turned positive, the stock continued to rise in of 43 cases over the following month. The odds of a continued upward trend are .

The 50-day moving average for BCAB moved above the 200-day moving average on September 29, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where BCAB advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 82 cases where BCAB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BCAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (37.736) is normal, around the industry mean (23.456). P/E Ratio (0.000) is within average values for comparable stocks, (54.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.164). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (3.926) is also within normal values, averaging (347.799).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCAB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
BCAB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

BCAB is expected to report earnings to fall 14.59% to -27 cents per share on November 05

BioAtla BCAB Stock Earnings Reports
Q3'25
Est.
$-0.27
Q2'25
Missed
by $0.06
Q1'25
Beat
by $0.13
Q4'24
Beat
by $0.08
Q3'24
Beat
by $0.19
The last earnings report on August 07 showed earnings per share of -31 cents, missing the estimate of -25 cents. With 3.77M shares outstanding, the current market capitalization sits at 47.24M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
11085 Torreyana Road
Phone
+1 858 558-0708
Employees
65
Web
https://www.bioatla.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NHNKY12.230.27
+2.28%
Nihon Kohden Corp.
ALEGF7.65N/A
N/A
ALLEGRO EU SA
ACMLF5.03N/A
N/A
Ascom Holding AG
PVFPF0.72N/A
N/A
Partners Value Invts LP
EMGDF0.23N/A
-1.74%
EMINENT GOLD CORP.

BCAB and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, BCAB has been loosely correlated with KYMR. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if BCAB jumps, then KYMR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BCAB
1D Price
Change %
BCAB100%
-12.00%
KYMR - BCAB
40%
Loosely correlated
-2.72%
CTMX - BCAB
37%
Loosely correlated
+0.59%
NVO - BCAB
35%
Loosely correlated
-1.46%
DNLI - BCAB
35%
Loosely correlated
+1.54%
GALT - BCAB
34%
Loosely correlated
-2.75%
More